NTRK1 and familial pancreatic carcinoma: Clinically, elevated expression of MET proto-oncogene, receptor tyrosine kinase (MET) and AXL receptor tyrosine kinase (AXL) or their ligands correlates with worse status in pancreatic cancer patients [10,11].